Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
medrxiv; 2023.
Preprint en Inglés | medRxiv | ID: ppzbmed-10.1101.2023.06.29.23292056

RESUMEN

Infections can lead to persistent or long-term symptoms and diseases such as shingles after varicella zoster, cancers after human papillomavirus, or rheumatic fever after streptococcal infections(1,2). Similarly, infection by SARS-CoV-2 can result in Long COVID, a condition characterized by symptoms of fatigue and pulmonary and cognitive dysfunction(3-5). The biological mechanisms that contribute to the development of Long COVID remain to be clarified. We leveraged the COVID-19 Host Genetics Initiative(6,7) to perform a genome-wide association study for Long COVID including up to 6,450 Long COVID cases and 1,093,995 population controls from 24 studies across 16 countries. We identified the first genome-wide significant association for Long COVID at the FOXP4 locus. FOXP4 has been previously associated with COVID-19 severity(6), lung function(8), and cancers(9), suggesting a broader role for lung function in the pathophysiology of Long COVID. While we identify COVID-19 severity as a causal risk factor for Long COVID, the impact of the genetic risk factor located in the FOXP4 locus could not be solely explained by its association to severe COVID-19. Our findings further support the role of pulmonary dysfunction and COVID-19 severity in the development of Long COVID.


Asunto(s)
Infecciones Estreptocócicas , Enfermedades Pulmonares , Neoplasias , Infecciones por Papillomavirus , COVID-19 , Trastornos del Conocimiento , Fiebre Reumática
2.
researchsquare; 2022.
Preprint en Inglés | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2398114.v1

RESUMEN

Background The severity of chest X-ray (CXR) findings is a prognostic factor in patients with coronavirus disease 2019 (COVID-19). However, the prognostic impact of deterioration of CXR findings and the clinical characteristics of patients with worsening CXR findings remain unclear. We aimed to investigate the clinical and genetic characteristics, as well as the prognosis, of patients with worsening CXR findings during early hospitalisation.Methods We retrospectively included 1656 consecutive Japanese patients with COVID-19 recruited through the Japan COVID-19 Task Force. Rapid deterioration of CXR findings was defined as increased pulmonary infiltrates in ≥ 50% of the lung fields within 48 h of admission.Results Rapid deterioration of CXR findings was an independent risk factor for death, most severe illness, tracheal intubation, and intensive care unit admission. The presence of consolidation on CXR, comorbid cardiovascular and chronic obstructive pulmonary diseases; high body temperature (≥ 37.7°C); and increased levels of serum aspartate aminotransferase (≥ 30 IU/L), potassium (≥ 4.3 mEq/L), and C-reactive protein (≥ 2.53 mg/dL) were independent risk factors for rapid deterioration of CXR findings. The risk variant at the ABO locus (rs529565-C) was associated with rapid deterioration of CXR findings in all patients with COVID-19. Further, the population-specific risk variant at the DOCK2 locus (rs60200309-A) was nominally associated with rapid deterioration of CXR findings in patients aged < 65 years.Conclusions This study revealed the clinical features, genetic features, and risk factors for rapid deterioration of CXR findings in patients with COVID-19. Rapid deterioration of CXR findings is a poor prognostic factor for patients with COVID-19.


Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica , Muerte , COVID-19
3.
researchsquare; 2022.
Preprint en Inglés | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-1838488.v1

RESUMEN

Background: An association between coronavirus disease 2019 (COVID-19) and ABO blood group has been reported. However, such an association has not been studied in the Japanese population on a large scale. Additionally, little is known about the association between COVID-19 and ABO genotype. Therefore, the present study aimed to investigate the association between COVID-19 and ABO blood group/genotype in a large Japanese population. Methods: All Japanese patients diagnosed with COVID-19 were recruited through the Japan COVID-19 Task Force between February 2020 and October 2021. We conducted a retrospective cohort study involving 1,790 COVID-19 Japanese patients whose DNA was used for genome-wide association study. We compared the ABO blood group/genotype in healthy population (n = 611, control) and COVID-19 patients, and then analyzed the association between the ABO blood group/genotype and clinical outcomes. Results: Blood group A was significantly more prevalent (41.6% vs. 36.8%) and group O was significantly less prevalent (26.2% vs. 30.8%) in the COVID-19 group than in the control group. Moreover, genotype OO was significantly less common in the COVID-19 group. Further, blood group AB was identified as an independent risk factor for most severe diseases compared with blood group O [aOR (95% CI) = 1.84 (1.00–3.37)]. Similarly, in ABO genotype analysis, only genotype AB was an independent risk factor for most severe disease compared with genotype OO. Conclusions: Blood group O is protective, whereas blood group A is associated with the risk of infection. Moreover, blood group AB is associated with the risk of ‘most’ severe disease. 


Asunto(s)
COVID-19
4.
Guillaume Butler-Laporte; Gundula Povysil; Jack Kosmicki; Elizabeth T Cirulli; Theodore Drivas; Simone Furini; Chadi Saad; Axel Schmidt; Pawel Olszewski; Urszula Korotko; Mathieu Quinodoz; Elifnaz Celik; Kousik Kundu; Klaudia Walter; Junghyung Jung; Amy D Stockwell; Laura G Sloofman; Alexander W Charney; Daniel Jordan; Noam Beckmann; Bartlomiej Przychodzen; Timothy Chang; Tess D Pottinger; Ning Shang; Fabian Brand; Francesca Fava; Francesca Mari; Karolina Chwialkowska; Magdalena Niemira; Szymon Pula; J Kenneth Baillie; Alex Stuckey; Andrea Ganna; Konrad J Karczewski; Kumar Veerapen; Mathieu Bourgey; Guillaume Bourque; Robert JM Eveleigh; Vincenzo Forgetta; David Morrison; David Langlais; Mark Lathrop; Vincent Mooser; Tomoko Nakanishi; Robert Frithiof; Michael Hultstrom; Miklos Lipcsey; Yanara Marincevic-Zuniga; Jessica Nordlund; Kelly M Schiabor Barrett; William Lee; Alexandre Bolze; Simon White; Stephen Riffle; Francisco Tanudjaja; Efren Sandoval; Iva Neveux; Shaun Dabe; Nicolas Casadei; Susanne Motameny; Manal Alaamery; Salam Massadeh; Nora Aljawini; Mansour S Almutairi; Yaseen M Arab; Saleh A Alqahtan; Fawz S Al Harthi; Amal Almutairi; Fatima Alqubaishi; Sarah Alotaibi; Albandari Binowayn; Ebtehal A Alsolm; Hadeel El Bardisy; Mohammad Fawzy; - COVID-19 Host Genetics Initiative; - DeCOI Host Genetics Group; - GEN-COVID Multicenter Study; - GenOMICC Consortium; - Japan COVID-19 Task Force; - Regeneron Genetics Center; Daniel H Geschwind; Stephanie Arteaga; Alexis Stephens; Manish J Butte; Paul C Boutros; Takafumi N Yamaguchi; Shu Tao; Stefan Eng; Timothy Sanders; Paul J Tung; Michael E Broudy; Yu Pan; Alfredo Gonzalez; Nikhil Chavan; Ruth Johnson; Bogdan Pasaniuc; Brian Yaspan; Sandra Smieszek; Carlo Rivolta; Stephanie Bibert; Pierre-Yves Bochud; Maciej Dabrowski; Pawel Zawadzki; Mateusz Sypniewski; El?bieta Kaja; Pajaree Chariyavilaskul; Voraphoj Nilaratanakul; Nattiya Hirankarn; Vorasuk Shotelersuk; Monnat Pongpanich; Chureerat Phokaew; Wanna Chetruengchai; Yosuke Kawai; Takanori Hasegawa; Tatsuhiko Naito; Ho Namkoong; Ryuya Edahiro; Akinori Kimura; Seishi Ogawa; Takanori Kanai; Koichi Fukunaga; Yukinori Okada; Seiya Imoto; Satoru Miyano; Serghei Mangul; Malak S Abedalthagafi; Hugo Zeberg; Joseph J Grzymski; Nicole L Washington; Stephan Ossowski; Kerstin U Ludwig; Eva C Schulte; Olaf Riess; Marcin Moniuszko; Miroslaw Kwasniewski; Hamdi Mbarek; Said I Ismail; Anurag Verma; David B Goldstein; Krzysztof Kiryluk; Alessandra Renieri; Manuel Ferreira; J Brent Richards.
medrxiv; 2022.
Preprint en Inglés | medRxiv | ID: ppzbmed-10.1101.2022.03.28.22273040

RESUMEN

Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,048 severe disease cases and 571,009 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41x10-7). These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.


Asunto(s)
COVID-19
5.
medrxiv; 2022.
Preprint en Inglés | medRxiv | ID: ppzbmed-10.1101.2022.01.06.22268711

RESUMEN

Using single-cell proteomics by mass cytometry, we investigate changes to a broad selection of over 10,000,000 immune cells in a cohort of moderate, severe, and critical Japanese COVID-19 patients and healthy controls with a particular focus on regulatory T-cells (Tregs). We find significant disruption within all compartments of the immune system and the emergence of atypical CTLA-4high CD4 T-cells and proliferating HLA-DRlowCD38high Tregs associated with critical patients. We also observed disrupted regulation of humoral immunity in COVID-19, with a loss of circulating T follicular regulatory T cells (Tfr) and altered T follicular helper (Tfh)/Tfr and plasma cell/Tfr ratios, all of which are significantly lower in male patients. Shifting ratios of CXCR4 and CXCR5 expression in B-cells provides further evidence of an autoimmune phenotype and dysregulated humoral immunity. These results suggest that Tregs are central to the changing cellular networks of a wide range of cells in COVID-19 and that sex specific differences to the balance of Tfr, Tfh and plasma cells may have important implications for the specificity of the humoral immune response to SARS-CoV-2.


Asunto(s)
COVID-19
6.
Ho Namkoong; Ryuya Edahiro; Koichi Fukunaga; Yuya Shirai; Kyuto Sonehara; Hiromu Tanaka; Ho Lee; Takanori Hasegawa; Masahiro Kanai; Tatsuhiko Naito; Kenichi Yamamoto; Ryunosuke Saiki; Takayoshi Hyugaji; Eigo Shimizu; Kotoe Katayama; Kazuhisa Takahashi; Norihiro Harada; Toshio Naito; Makoto Hiki; Yasushi Matsushita; Haruhi Takagi; Ryousuke Aoki; Ai Nakamura; Sonoko Harada; Hitoshi Sasano; Hiroki Kabata; Katsunori Masaki; Hirofumi Kamata; Shinnosuke Ikemura; Shotaro Chubachi; Satoshi Okamori; Hideki Terai; Atsuho Morita; Takanori Asakura; Junichi Sasaki; Hiroshi Morisaki; Yoshifumi Uwamino; Kosaku Nanki; Yohei Mikami; Sho Uchida; Shunsuke Uno; Rino Ishihara; Yuta Matsubara; Tomoyasu Nishimura; Takanori Ogawa; Takashi Ishiguro; Taisuke Isono; Shun Shibata; Yuma Matsui; Chiaki Hosoda; Kenji Takano; Takashi Nishida; Yoichi Kobayashi; Yotaro Takaku; Noboru Takayanagi; Soichiro Ueda; Ai Tada; Masayoshi Miyawaki; Masaomi Yamamoto; Eriko Yoshida; Reina Hayashi; Tomoki Nagasaka; Sawako Arai; Yutaro Kaneko; Kana Sasaki; Etsuko Tagaya; Masatoshi Kawana; Ken Arimura; Kunihiko Takahashi; Tatsuhiko Anzai; Satoshi Ito; Akifumi Endo; Yuji Uchimura; Yasunari Miyazaki; Takayuki Honda; Tomoya Tateishi; Shuji Tohda; Naoya Ichimura; Kazunari Sonobe; Chihiro Sassa; Jun Nakajima; Yasushi Nakano; Yukiko Nakajima; Ryusuke Anan; Ryosuke Arai; Yuko Kurihara; Yuko Harada; Kazumi Nishio; Tetsuya Ueda; Masanori Azuma; Ryuichi Saito; Toshikatsu Sado; Yoshimune Miyazaki; Ryuichi Sato; Yuki Haruta; Tadao Nagasaki; Yoshinori Yasui; Yoshinori Hasegawa; Yoshikazu Mutoh; Tomonori Sato; Reoto Takei; Satoshi Hagimoto; Yoichiro Noguchi; Yasuhiko Yamano; Hajime Sasano; Sho Ota; Yasushi Nakamori; Kazuhisa Yoshiya; Fukuki Saito; Tomoyuki Yoshihara; Daiki Wada; Hiromu Iwamura; Syuji Kanayama; Shuhei Maruyama; Takashi Yoshiyama; Ken Ohta; Hiroyuki Kokuto; Hideo Ogata; Yoshiaki Tanaka; Kenichi Arakawa; Masafumi Shimoda; Takeshi Osawa; Hiroki Tateno; Isano Hase; Shuichi Yoshida; Shoji Suzuki; Miki Kawada; Hirohisa Horinouchi; Fumitake Saito; Keiko Mitamura; Masao Hagihara; Junichi Ochi; Tomoyuki Uchida; Rie Baba; Daisuke Arai; Takayuki Ogura; Hidenori Takahashi; Shigehiro Hagiwara; Genta Nagao; Shunichiro Konishi; Ichiro Nakachi; Koji Murakami; Mitsuhiro Yamada; Hisatoshi Sugiura; Hirohito Sano; Shuichiro Matsumoto; Nozomu Kimura; Yoshinao Ono; Hiroaki Baba; Yusuke Suzuki; Sohei Nakayama; Keita Masuzawa; Shinichi Namba; Ken Suzuki; Nobuyuki Hizawa; Takayuki Shiroyama; Satoru Miyawaki; Yusuke Kawamura; Akiyoshi Nakayama; Hirotaka Matsuo; Yuichi Maeda; Takuro Nii; Yoshimi Noda; Takayuki Niitsu; Yuichi Adachi; Takatoshi Enomoto; Saori Amiya; Reina Hara; Toshihiro Kishikawa; Shuhei Yamada; Shuhei Kawabata; Noriyuki Kijima; Masatoshi Takagaki; Noa Sasa; Yuya Ueno; Motoyuki Suzuki; Norihiko Takemoto; Hirotaka Eguchi; Takahito Fukusumi; Takao Imai; Munehisa Fukushima; Haruhiko Kishima; Hidenori Inohara; Kazunori Tomono; Kazuto Kato; Meiko Takahashi; Fumihiko Matsuda; Haruhiko Hirata; Yoshito Takeda; Hidefumi Koh; Tadashi Manabe; Yohei Funatsu; Fumimaro Ito; Takahiro Fukui; Keisuke Shinozuka; Sumiko Kohashi; Masatoshi Miyazaki; Tomohisa Shoko; Mitsuaki Kojima; Tomohiro Adachi; Motonao Ishikawa; Kenichiro Takahashi; Takashi Inoue; Toshiyuki Hirano; Keigo Kobayashi; Hatsuyo Takaoka; Kazuyoshi Watanabe; Naoki Miyazawa; Yasuhiro Kimura; Reiko Sado; Hideyasu Sugimoto; Akane Kamiya; Naota Kuwahara; Akiko Fujiwara; Tomohiro Matsunaga; Yoko Sato; Takenori Okada; Yoshihiro Hirai; Hidetoshi Kawashima; Atsuya Narita; Kazuki Niwa; Yoshiyuki Sekikawa; Koichi Nishi; Masaru Nishitsuji; Mayuko Tani; Junya Suzuki; Hiroki Nakatsumi; Takashi Ogura; Hideya Kitamura; Eri Hagiwara; Kota Murohashi; Hiroko Okabayashi; Takao Mochimaru; Shigenari Nukaga; Ryosuke Satomi; Yoshitaka Oyamada; Nobuaki Mori; Tomoya Baba; Yasutaka Fukui; Mitsuru Odate; Shuko Mashimo; Yasushi Makino; Kazuma Yagi; Mizuha Hashiguchi; Junko Kagyo; Tetsuya Shiomi; Satoshi Fuke; Hiroshi Saito; Tomoya Tsuchida; Shigeki Fujitani; Mumon Takita; Daiki Morikawa; Toru Yoshida; Takehiro Izumo; Minoru Inomata; Naoyuki Kuse; Nobuyasu Awano; Mari Tone; Akihiro Ito; Yoshihiko Nakamura; Kota Hoshino; Junichi Maruyama; Hiroyasu Ishikura; Tohru Takata; Toshio Odani; Masaru Amishima; Takeshi Hattori; Yasuo Shichinohe; Takashi Kagaya; Toshiyuki Kita; Kazuhide Ohta; Satoru Sakagami; Kiyoshi Koshida; Kentaro Hayashi; Tetsuo Shimizu; Yutaka Kozu; Hisato Hiranuma; Yasuhiro Gon; Namiki Izumi; Kaoru Nagata; Ken Ueda; Reiko Taki; Satoko Hanada; Kodai Kawamura; Kazuya Ichikado; Kenta Nishiyama; Hiroyuki Muranaka; Kazunori Nakamura; Naozumi Hashimoto; Keiko Wakahara; Sakamoto Koji; Norihito Omote; Akira Ando; Nobuhiro Kodama; Yasunari Kaneyama; Shunsuke Maeda; Takashige Kuraki; Takemasa Matsumoto; Koutaro Yokote; Taka-Aki Nakada; Ryuzo Abe; Taku Oshima; Tadanaga Shimada; Masahiro Harada; Takeshi Takahashi; Hiroshi Ono; Toshihiro Sakurai; Takayuki Shibusawa; Yoshifumi Kimizuka; Akihiko Kawana; Tomoya Sano; Chie Watanabe; Ryohei Suematsu; Hisako Sageshima; Ayumi Yoshifuji; Kazuto Ito; Saeko Takahashi; Kota Ishioka; Morio Nakamura; Makoto Masuda; Aya Wakabayashi; Hiroki Watanabe; Suguru Ueda; Masanori Nishikawa; Yusuke Chihara; Mayumi Takeuchi; Keisuke Onoi; Jun Shinozuka; Atsushi Sueyoshi; Yoji Nagasaki; Masaki Okamoto; Sayoko Ishihara; Masatoshi Shimo; Yoshihisa Tokunaga; Yu Kusaka; Takehiko Ohba; Susumu Isogai; Aki Ogawa; Takuya Inoue; Satoru Fukuyama; Yoshihiro Eriguchi; Akiko Yonekawa; Keiko Kan-o; Koichiro Matsumoto; Kensuke Kanaoka; Shoichi Ihara; Kiyoshi Komuta; Yoshiaki Inoue; Shigeru Chiba; Kunihiro Yamagata; Yuji Hiramatsu; Hirayasu Kai; Koichiro Asano; Tsuyoshi Oguma; Yoko Ito; Satoru Hashimoto; Masaki Yamasaki; Yu Kasamatsu; Yuko Komase; Naoya Hida; Takahiro Tsuburai; Baku Oyama; Minoru Takada; Hidenori Kanda; Yuichiro Kitagawa; Tetsuya Fukuta; Takahito Miyake; Shozo Yoshida; Shinji Ogura; Shinji Abe; Yuta Kono; Yuki Togashi; Hiroyuki Takoi; Ryota Kikuchi; Shinichi Ogawa; Tomouki Ogata; Shoichiro Ishihara; Arihiko Kanehiro; Shinji Ozaki; Yasuko Fuchimo; Sae Wada; Nobukazu Fujimoto; Kei Nishiyama; Mariko Terashima; Satoru Beppu; Kosuke Yoshida; Osamu Narumoto; Hideaki Nagai; Nobuharu Ooshima; Mitsuru Motegi; Akira Umeda; Kazuya Miyagawa; Hisato Shimada; Mayu Endo; Yoshiyuki Ohira; Masafumi Watanabe; Sumito Inoue; Akira Igarashi; Masamichi Sato; Hironori Sagara; Akihiko Tanaka; Shin Ohta; Tomoyuki Kimura; Yoko Shibata; Yoshinori Tanino; Takefumi Nikaido; Hiroyuki Minemura; Yuki Sato; Yuichiro Yamada; Takuya Hashino; Masato Shinoki; Hajime Iwagoe; Hiroshi Takahashi; Kazuhiko Fujii; Hiroto Kishi; Masayuki Kanai; Tomonori Imamura; Tatsuya Yamashita; Masakiyo Yatomi; Toshitaka Maeno; Shinichi Hayashi; Mai Takahashi; Mizuki Kuramochi; Isamu Kamimaki; Yoshiteru Tominaga; Tomoo Ishii; Mitsuyoshi Utsugi; Akihiro Ono; Toru Tanaka; Takeru Kashiwada; Kazue Fujita; Yoshinobu Saito; Masahiro Seike; Yosuke Omae; Yasuhito Nannya; Takafumi Ueno; Tomomi Takano; Kazuhiko Katayama; Masumi Ai; Atsushi Kumanogoh; Toshiro Sato; Naoki Hasegawa; Katsushi Tokunaga; Makoto Ishii; Ryuji Koike; Yuko Kitagawa; Akinori Kimura; Seiya Imoto; Satoru Miyano; Seishi Ogawa; Takanori Kanai; Yukinori Okada.
medrxiv; 2021.
Preprint en Inglés | medRxiv | ID: ppzbmed-10.1101.2021.05.17.21256513

RESUMEN

To elucidate the host genetic loci affecting severity of SARS-CoV-2 infection, or Coronavirus disease 2019 (COVID-19), is an emerging issue in the face of the current devastating pandemic. Here, we report a genome-wide association study (GWAS) of COVID-19 in a Japanese population led by the Japan COVID-19 Task Force, as one of the initial discovery GWAS studies performed on a non-European population. Enrolling a total of 2,393 cases and 3,289 controls, we not only replicated previously reported COVID-19 risk variants (e.g., LZTFL1, FOXP4, ABO, and IFNAR2), but also found a variant on 5p35 (rs60200309-A at DOCK2) that was significantly associated with severe COVID-19 in younger (<65 years of age) patients with a genome-wide significant p-value of 1.2 x 10-8 (odds ratio = 2.01, 95% confidence interval = 1.58-2.55). This risk allele was prevalent in East Asians, including Japanese (minor allele frequency [MAF] = 0.097), but rarely found in Europeans. Cross-population Mendelian randomization analysis made a causal inference of a number of complex human traits on COVID-19. In particular, obesity had a significant impact on severe COVID-19. The presence of the population-specific risk allele underscores the need of non-European studies of COVID-19 host genetics.


Asunto(s)
Obesidad , COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA